A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma

被引：0
|
作者：
A. F. Cardona
L. Rojas
B. Wills
A. Ruiz-Patiño
L. Abril
F. Hakim
E. Jiménez
N. Useche
S. Bermúdez
J. A. Mejía
J. F. Ramón
H. Carranza
C. Vargas
J. Otero
P. Archila
J. Rodríguez
J. Rodríguez
J. Behaine
D. González
J. Jacobo
H. Cifuentes
O. Feo
P. Penagos
D. Pineda
L. Ricaurte
L. E. Pino
C. Vargas
J. C. Marquez
M. I. Mantilla
L. D. Ortiz
C. Balaña
R. Rosell
Z. L. Zatarain-Barrón
O. Arrieta
机构：
[1] Clínica del Country,Clinical and Translational Oncology Group, Institute of Oncology
[2] Foundation for Clinical and Applied Cancer Research (FICMAC),Institute of Neuroscience
[3] Universidad El Bosque,Clinical Oncology Department, Centro Javeriano de Oncología
[4] Hospital Universitario San Ignacio,Faculty of Medicine
[5] Pontificia Universidad Javeriana,Internal Medicine Department
[6] Johns Hopkins University,Neurosurgery Department
[7] Fundación Santa Fe de Bogotá,Division of Neuro
[8] Fundación Santa Fe de Bogotá,radiology, Radiology Department
[9] Clínica del Country,Neurosurgery Department
[10] National Cancer Institute (INC),Neurosurgery Department
[11] Clínica del Country,Division of Neuro
[12] Fundación Santa fe de Bogotá,radiology, Radiology Department
[13] Clínica de Las Américas,Clinical Oncology Department
[14] Hospital Germans Trias i Pujol,Division of Neuro
[15] Instituto Nacional de Cancerología,Oncology, Clinical Oncology Department
来源：
Clinical and Translational Oncology | 2019年 / 21卷
关键词：
Glioblastoma; Second-line therapy; Bevacizumab; Molecular expression classification;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1364 / 1373
页数：9
相关论文
共 50 条
  • [1] A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma
    Cardona, A. F.
    Rojas, L.
    Wills, B.
    Ruiz-Patino, A.
    Abril, L.
    Hakim, F.
    Jimenez, E.
    Useche, N.
    Bermudez, S.
    Mejia, J. A.
    Ramon, J. F.
    Carranza, H.
    Vargas, C.
    Otero, J.
    Archila, P.
    Rodriguez, J.
    Rodriguez, J.
    Behaine, J.
    Gonzalez, D.
    Jacobo, J.
    Cifuentes, H.
    Feo, O.
    Penagos, P.
    Pineda, D.
    Ricaurte, L.
    Pino, L. E.
    Vargas, C.
    Marquez, J. C.
    Mantilla, M. I.
    Ortiz, L. D.
    Balana, C.
    Rosell, R.
    Zatarain-Barron, Z. L.
    Arrieta, O.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (10): : 1364 - 1373
  • [2] Profiling response to carmustine/bevacizumab in recurrent glioblastoma.
    Rojas, Leonardo
    Cardona, Andres F.
    Wills, Beatriz
    Arrieta, Oscar
    Vargas, Carlos A.
    Carranza, Hernan
    Otero, Jorge M.
    Useche, Nicolas
    Bermudez, Sonia
    Jimenez, Enrique
    Hakim, Fernando
    Balana, Carmen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab
    Rahman, Rifaquat
    Hempfling, Kelly
    Norden, Andrew D.
    Reardon, David A.
    Nayak, Lakshmi
    Rinne, Mikael L.
    Beroukhim, Rameen
    Doherty, Lisa
    Ruland, Sandra
    Rai, Arun
    Rifenburg, Jennifer
    LaFrankie, Debra
    Alexander, Brian M.
    Huang, Raymond Y.
    Wen, Patrick Y.
    Lee, Eudocia Q.
    [J]. NEURO-ONCOLOGY, 2014, 16 (11) : 1523 - 1529
  • [4] Prognostic factors in recurrent glioblastoma patients treated with bevacizumab
    Schaub, Christina
    Tichy, Julia
    Schaefer, Niklas
    Franz, Kea
    Mack, Frederic
    Mittelbronn, Michel
    Kebir, Sied
    Thiepold, Anna-Luisa
    Waha, Andreas
    Filmann, Natalie
    Banat, Mohammed
    Fimmers, Rolf
    Steinbach, Joachim P.
    Herrlinger, Ulrich
    Rieger, Johannes
    Glas, Martin
    Baehr, Oliver
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2016, 129 (01) : 93 - 100
  • [5] Prognostic factors in recurrent glioblastoma patients treated with bevacizumab
    Christina Schaub
    Julia Tichy
    Niklas Schäfer
    Kea Franz
    Frederic Mack
    Michel Mittelbronn
    Sied Kebir
    Anna-Luisa Thiepold
    Andreas Waha
    Natalie Filmann
    Mohammed Banat
    Rolf Fimmers
    Joachim P. Steinbach
    Ulrich Herrlinger
    Johannes Rieger
    Martin Glas
    Oliver Bähr
    [J]. Journal of Neuro-Oncology, 2016, 129 : 93 - 100
  • [6] RETROSPECTIVE ANALYSIS OF LONG-TERM RESPONSE TO BEVACIZUMAB IN COMBINATION WITH IRINOTECAN FOR RECURRENT GLIOBLASTOMA: IDENTIFICATION OF PROGNOSTIC FACTORS
    Besson, C.
    Morisse, M.
    Brut, H.
    Waissi, W.
    Noel, G.
    Chauffert, B.
    Prebay, D.
    Schott, R.
    Etienne-Selloum, N.
    [J]. NEURO-ONCOLOGY, 2019, 21 : 98 - 98
  • [7] Molecular analysis of a recurrent glioblastoma treated with bevacizumab
    Furuta, Takuya
    Nakada, Mitsutoshi
    Misaki, Kouichi
    Sato, Yasunori
    Hayashi, Yutaka
    Nakanuma, Yasuni
    Hamada, Jun-ichiro
    [J]. BRAIN TUMOR PATHOLOGY, 2014, 31 (01) : 32 - 39
  • [8] Bevacizumab in recurrent glioblastoma
    Martinez, Nina L.
    Glass, Jon
    Shi, Wenyin
    [J]. TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S162 - S163
  • [9] Molecular analysis of a recurrent glioblastoma treated with bevacizumab
    Takuya Furuta
    Mitsutoshi Nakada
    Kouichi Misaki
    Yasunori Sato
    Yutaka Hayashi
    Yasuni Nakanuma
    Jun-ichiro Hamada
    [J]. Brain Tumor Pathology, 2014, 31 : 32 - 39
  • [10] Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment
    Pope, Whitney B.
    Kim, Hyun J.
    Huo, Jing
    Alger, Jeffry
    Brown, Matthew S.
    Gjertson, David
    Sai, Victor
    Young, Jonathan R.
    Tekchandani, Leena
    Cloughesy, Timothy
    Mischel, Paul S.
    Lai, Albert
    Nghiemphu, Phioanh
    Rahmanuddin, Syed
    Goldin, Jonathan
    [J]. RADIOLOGY, 2009, 252 (01) : 182 - 189
12345